Drugs / SCM-CGH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04189432 | Sep 2016 → Mar 2024 | chronic graft versus host disease | SCM Lifescience Co., LTD. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCM-CGH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04189432 ↗ |
| Modality | Cell therapy | “Ingredient: Allogeneic human bone marrow-derived mesenchymal stem cells” NCT04189432 ↗ |
| Route | Intravenous | “by IV infusion” NCT04189432 ↗ |